A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
NCT05702034
Recruiting
The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
04/25/2025
Locations: Banner Desert Medical Center, Mesa, Arizona +827 locations
Conditions: Ischemic Stroke; Ischemic Attack, Transient
Register for Updates
Study of BEST1 Vitelliform Macular Dystrophy
NCT05809635
Recruiting
The purpose of this study is to establish the natural history of of participants with BESTROPHIN 1 Vitelliform Macular Dystrophy. The blinding disorder Best Vitelliform Macular Dystrophy (VMD) is caused by any one of more than 250 different mutations in the BEST1 gene. As new treatments are developed, a clear understanding of the natural history of disease progression of BEST1 VMD is necessary. The goals of this natural history study are to: 1. Report the natural history of retinal degenerati... Read More
Gender:
ALL
Ages:
All
Trial Updated:
04/25/2025
Locations: Columbia University Irving Medical Center, New York, New York +2 locations
Conditions: Best Vitelliform Macular Dystrophy, Retinitis Pigmentosa
Register for Updates
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
NCT05902169
Recruiting
The brain is protected from any toxic or inflammatory molecule by the blood-brain barrier (BBB). This physical barrier is located at the level of the blood vessel walls. Because of these barrier properties, the blood vessels are also impermeable to the passage of therapeutic molecules from the blood to the brain. The development of effective treatments against glioblastoma is thus limited due to the BBB that prevents most drugs injected in the bloodstream from getting into brain tissue where the... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Mayo Clinic Arizona, Phoenix, Arizona +38 locations
Conditions: Glioblastoma, Recurrent Glioblastoma, GBM
Register for Updates
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A
NCT05987449
Recruiting
WP44714 is a Phase I/II, open-label, non-randomized, global, multicenter trial consisting of two parts: * Part 1 is a multiple-ascending dose (MAD) study in adult and adolescent male participants with severe or moderate hemophilia A with or without factor VIII (FVIII) inhibitors. * Part 2 is a multiple-dose study in pediatric male participants with severe or moderate hemophilia A with or without FVIII inhibitors. The overall aim of the study is to investigate the safety, tolerability, pharmaco... Read More
Gender:
MALE
Ages:
Between 2 years and 59 years
Trial Updated:
04/25/2025
Locations: UC Davis Cancer Center, Sacramento, California +11 locations
Conditions: Hemophilia A
Register for Updates
Enhancing PTSD Treatment Outcomes by Improving Patient-Provider Communication
NCT06088303
Recruiting
The purpose of this clinical trial is to learn whether existing treatments for posttraumatic stress disorder (PTSD) can be improved. Two treatments for PTSD, cognitive processing therapy (CPT) and prolonged exposure (PE) will be studied. CPT and PE are effective treatments that are widely available, but interventions are needed to improve patient outcomes in these treatments. The investigators have developed an Adjunctive Writing intervention for Amplifying Response and Engagement (AWARE), which... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: National Center for PTSD at VA Boston Healthcare System, Boston, Massachusetts
Conditions: Stress Disorders, Post-Traumatic
Register for Updates
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
NCT06208150
Recruiting
The purpose of this study is to compare the effectiveness of either talquetamab plus pomalidomide (Tal-P) or talquetamab plus teclistamab (Tal-Tec) with elotuzumab, pomalidomide, and dexamethasone (EPd) or pomalidomide, bortezomib, and dexamethasone (PVd).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: UCSF Fresno, Clovis, California +219 locations
Conditions: Relapsed or Refractory Multiple Myeloma
Register for Updates
Chest Drain Regular Flushing in Complicated Parapneumonic Effusions and Empyemas
NCT06427538
Recruiting
Infections of the pleural space are common, and patients require antibiotics and chest drain placement to evacuate the chest from the infected fluid. Chest drains can get blocked by the drainage fluid and material. For this reason, it is thought that flushing the chest drain with saline solution, can help maintain the patency of the tube. This proposed study will evaluate the impact of regular chest drain flushing on the length of time to chest tube removal and total hospitalization as well as i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Mount Sinai, New York City, New York +2 locations
Conditions: Empyema, Pleural, Pleural Infection
Register for Updates
Informing Pain Treatment Using Pharmacogenomic Analysis
NCT06511401
Recruiting
This is a randomized, prospective study to evaluate the effects of preemptive pharmacogenomic (PGx) testing on opioid dosing decisions/selections and pain score in cancer patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois
Conditions: Adult Patients Who Are Receiving Oncologic Care
Register for Updates
Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients
NCT06538038
Recruiting
The goal of the study is to collect data on patients treated outside of a clinical trial (in routine clinical practice) with standard of care osimertinib with or without chemotherapy in Epidermal Growth Factor Receptor (EGFR)-mutant Non-Small Cell Lung Cancer (NSCLC) to better understand the safety and effectiveness of these standard of care regimens.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Mercy Clinic Fort Smith Communities, Fort Smith, Arkansas +72 locations
Conditions: Non Small Cell Lung Cancer, Epidermal Growth Factor Receptor Gene Mutation, Stage III Lung Cancer, Stage IV Lung Cancer
Register for Updates
Evaluation of Parent Toolkit 2.0 (Morehouse Family Health Study)
NCT06579781
Recruiting
Child Trends will conduct a randomized control trial evaluation of Parent Toolkit 2.0, an innovative intervention for parents and caregivers of middle and high school students. Child Trends will collaborate with Morehouse School of Medicine and Tressa Tucker \& Associates, LLC to implement and evaluate the program with 1,000 parent-teen pairs across Georgia. The program includes three components that will be delivered across a three-week period: (1) an online self-paced Parent Guide with informa... Read More
Gender:
ALL
Ages:
Between 12 years and 15 years
Trial Updated:
04/25/2025
Locations: Community Outreach, Cairo, Georgia
Conditions: Sexual Behavior, Adolescent Behavior, Sexually Transmitted Diseases, Contraception Behavior, Parent-Child Relations
Register for Updates
Heat, Microvascular Function and Aging
NCT06633198
Recruiting
Vascular dysfunction is a common factor in many chronic debilitating diseases, contributing to morbidity and mortality. With the onset of chronic disease or exposure to stress, the vasculature displays an inability to adequately respond to increased blood flow demands, manifesting in a reduced ability or altered mechanism of vasodilation. Aging is an independent risk factor in the development of cardiovascular disease, and reduces vasodilator capacity, or alters the mechanism by which vasodilati... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/25/2025
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Aging
Register for Updates
Study of 68Ga-R10602
NCT06745804
Recruiting
A phase 1 imaging study of 68Ga-R10602 in hormone-receptor positive breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana +1 locations
Conditions: Locoregionally Recurrent Hormone-receptor Positive Breast Cancer, Metastatic Hormone Receptor Positive Breast Cancer
Register for Updates